Geron Corp. Stock
Price
Target price
€3.24
€3.24
-0.430%
-0.014
-0.430%
€4.59
15:07 / Tradegate
WKN: 902213 / Symbol: GERN / Name: Geron / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Geron Corp. Stock
Geron Corp. shows a slight decrease today, losing -€0.014 (-0.430%) compared to yesterday.
Geron Corp. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
As a result the target price of 4 € shows a positive potential of 23.57% compared to the current price of 3.24 € for Geron Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Geron Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Geron Corp. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Geron Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Geron Corp. | -0.430% | 6.138% | 5.006% | 76.493% | 65.193% | 158.426% | 95.843% |
| Ardelyx Inc. | -0.970% | -5.210% | -13.459% | 49.277% | 10.796% | -11.669% | - |
| Salarius Pharmaceuticals Inc. | 5.880% | -0.971% | -34.720% | -69.778% | -26.486% | -98.400% | -99.995% |
| Evolus Inc | -2.630% | -8.197% | -12.500% | 43.590% | 19.786% | 18.519% | - |
Comments
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $4.00 to $5.00. They now have a "buy" rating on the stock.
Show more
Ratings data for GERN provided by MarketBeat
News
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. (NASDAQ: GERN) is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their
Geron (GERN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q4 2023 Earnings CallFeb 28, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Geron (GERN) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q3 2023 Earnings CallNov 02, 2023, 9:00 a.m. ET
Operator
Source Fool.com